Pharmacokinetics and virological efficacy after switch to once-daily lopinavir/r in 1 treatment-experienced HIV-1 infected children. 2
BACKGROUND: There are few data on plasma and intracellular pharmacokinetics (PK) of once-daily (q24h...
The safety, pharmacokinetics, and antiviral activity of lopinavir, a human immunodeficiency virus (H...
BACKGROUND: There are few data on plasma and intracellular pharmacokinetics (PK) of once-daily (q24h...
Lopinavir-ritonavir (LPV/r) is a protease inhibitor that is used twice daily (BID) in the treatment ...
INTRODUCTION: Lopinavir is an HIV protease inhibitor that is co-formulated with ritonavir. The appro...
BACKGROUND: The use of lopinavir/ritonavir once-daily (LPV/r QD) has not been approved for children....
BACKGROUND: Lopinavir/ritonavir (LPV/r) has been licensed for the treatment of HIV-infected children...
Contains fulltext : 50981.pdf (publisher's version ) (Closed access)INTRODUCTION: ...
Contains fulltext : 176929.pdf (publisher's version ) (Closed access)BACKGROUND: T...
To evaluate the long-term safety and effectiveness of lopinavir/ritonavir (LPV/r) in a population-ba...
BACKGROUND: Lopinavir/ritonavir (LPV/r) pediatric tablets (100/25 mg) are approved by the United Sta...
BACKGROUND: Lopinavir/ritonavir is a common protease inhibitor (PI) used for second-line regimens in...
AIM: To evaluate the long-term safety and effectiveness of lopinavir/ritonavir (LPV/r) in a populati...
AIM: To evaluate the long-term safety and effectiveness of lopinavir/ritonavir (LPV/r) in a populati...
Contains fulltext : 152551.pdf (publisher's version ) (Open Access
BACKGROUND: There are few data on plasma and intracellular pharmacokinetics (PK) of once-daily (q24h...
The safety, pharmacokinetics, and antiviral activity of lopinavir, a human immunodeficiency virus (H...
BACKGROUND: There are few data on plasma and intracellular pharmacokinetics (PK) of once-daily (q24h...
Lopinavir-ritonavir (LPV/r) is a protease inhibitor that is used twice daily (BID) in the treatment ...
INTRODUCTION: Lopinavir is an HIV protease inhibitor that is co-formulated with ritonavir. The appro...
BACKGROUND: The use of lopinavir/ritonavir once-daily (LPV/r QD) has not been approved for children....
BACKGROUND: Lopinavir/ritonavir (LPV/r) has been licensed for the treatment of HIV-infected children...
Contains fulltext : 50981.pdf (publisher's version ) (Closed access)INTRODUCTION: ...
Contains fulltext : 176929.pdf (publisher's version ) (Closed access)BACKGROUND: T...
To evaluate the long-term safety and effectiveness of lopinavir/ritonavir (LPV/r) in a population-ba...
BACKGROUND: Lopinavir/ritonavir (LPV/r) pediatric tablets (100/25 mg) are approved by the United Sta...
BACKGROUND: Lopinavir/ritonavir is a common protease inhibitor (PI) used for second-line regimens in...
AIM: To evaluate the long-term safety and effectiveness of lopinavir/ritonavir (LPV/r) in a populati...
AIM: To evaluate the long-term safety and effectiveness of lopinavir/ritonavir (LPV/r) in a populati...
Contains fulltext : 152551.pdf (publisher's version ) (Open Access
BACKGROUND: There are few data on plasma and intracellular pharmacokinetics (PK) of once-daily (q24h...
The safety, pharmacokinetics, and antiviral activity of lopinavir, a human immunodeficiency virus (H...
BACKGROUND: There are few data on plasma and intracellular pharmacokinetics (PK) of once-daily (q24h...